A detailed history of Advisors Management Group Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Advisors Management Group Inc holds 7,009 shares of BMY stock, worth $404,279. This represents 0.09% of its overall portfolio holdings.

Number of Shares
7,009
Previous 7,008 0.01%
Holding current value
$404,279
Previous $291,000 24.74%
% of portfolio
0.09%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$39.66 - $51.75 $39 - $51
1 Added 0.01%
7,009 $363,000
Q2 2024

Jul 31, 2024

SELL
$40.25 - $52.99 $4,749 - $6,252
-118 Reduced 1.66%
7,008 $291,000
Q1 2024

Apr 26, 2024

SELL
$47.98 - $54.4 $18,760 - $21,270
-391 Reduced 5.2%
7,126 $386,000
Q4 2023

Jan 26, 2024

SELL
$48.48 - $57.85 $9,696 - $11,570
-200 Reduced 2.59%
7,517 $386,000
Q3 2023

Oct 17, 2023

BUY
$57.89 - $64.73 $74,157 - $82,919
1,281 Added 19.9%
7,717 $448,000
Q1 2023

Apr 26, 2023

SELL
$65.71 - $74.53 $8,410 - $9,539
-128 Reduced 1.95%
6,436 $446,000
Q4 2022

Feb 03, 2023

BUY
$68.48 - $81.09 $5,957 - $7,054
87 Added 1.34%
6,564 $472,000
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $10 - $5,916
77 Added 1.2%
6,477 $460,000
Q2 2022

Aug 03, 2022

BUY
$72.62 - $79.98 $13,652 - $15,036
188 Added 3.03%
6,400 $493,000
Q1 2022

Apr 20, 2022

SELL
$61.48 - $73.72 $11,312 - $13,564
-184 Reduced 2.88%
6,212 $454,000
Q4 2021

Jan 31, 2022

BUY
$53.63 - $62.52 $14,533 - $16,942
271 Added 4.42%
6,396 $399,000
Q3 2021

Oct 28, 2021

SELL
$59.17 - $69.31 $8,993 - $10,535
-152 Reduced 2.42%
6,125 $362,000
Q2 2021

Jul 21, 2021

BUY
$61.91 - $67.42 $121,343 - $132,143
1,960 Added 45.4%
6,277 $419,000
Q1 2021

Apr 14, 2021

BUY
$59.34 - $66.74 $256,170 - $288,116
4,317 New
4,317 $273,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Advisors Management Group Inc Portfolio

Follow Advisors Management Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Management Group Inc , based on Form 13F filings with the SEC.

News

Stay updated on Advisors Management Group Inc with notifications on news.